Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Biovitrum AB (STO:BVT) Biovitrum would like to invite you to a press and analyst meeting in Stockholm on Wednesday, October 22, in conjunction with the disclosure of the Interim Report January - September 2008. The report will be presented by Biovitrum's CEO Martin Nicklasson and CFO Göran Arvidson. The presentation will be held in English and webcasted.
Time: Wednesday, October 22, 2008 at 3 p.m. (CET)
Venue: Berns salonger, Berzelii park, Stockholm (room :Kilsalen) Coffee will be served The report will be published at 8.30 a.m. (CET) the same day.
Participation:
If you wish to participate please notify Lotta Nerblad, e-mail lotta@zoomvision.se or mobile: +46 8 588 318 53. ___________________________________________________________________
Internet broadcast: A live broadcast from the presentation will be available on Internet, October 22 at 3 p.m. (CET): www.biovitrum.com
Telephone conference call: You may also participate with questions by telephone.
The presentation material will be published at our website after the meeting were you also can replay the webcast on demand, please got to : www.biovitrum.com.
About Biovitrum Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals primarily in the Nordic countries. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities include development and production of biotechnology therapeutics, as well as small molecule discovery and development. With revenues of approximately SEK 1.3 billion and around 500 employees, Biovitrum is a significant European specialty pharmaceutical player. Biovitrum's share is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
